MCID: PDT016
MIFTS: 29

Pediatric Infratentorial Ependymoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Pediatric Infratentorial Ependymoma

MalaCards integrated aliases for Pediatric Infratentorial Ependymoma:

Name: Pediatric Infratentorial Ependymoma 12 15
Childhood Infratentorial Ependymoma 72

Classifications:



External Ids:

Disease Ontology 12 DOID:7501
NCIt 50 C9041
UMLS 72 C0278599

Summaries for Pediatric Infratentorial Ependymoma

MalaCards based summary : Pediatric Infratentorial Ependymoma, also known as childhood infratentorial ependymoma, is related to benign ependymoma and ependymoma, and has symptoms including vomiting, headache and nausea. An important gene associated with Pediatric Infratentorial Ependymoma is MIR106B (MicroRNA 106b), and among its related pathways/superpathways are MicroRNAs in cancer and DNA Damage Response. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and bone.

Related Diseases for Pediatric Infratentorial Ependymoma

Diseases related to Pediatric Infratentorial Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 benign ependymoma 10.2
2 ependymoma 10.2
3 ataxia and polyneuropathy, adult-onset 10.1
4 dysphagia 10.1
5 hypotonia 10.1
6 kidney cancer 10.0 MIR17 MIR106B
7 glioma 9.1 MIR19A MIR17 EGFR
8 medulloblastoma 8.9 MIR19A MIR17 EGFR

Graphical network of the top 20 diseases related to Pediatric Infratentorial Ependymoma:



Diseases related to Pediatric Infratentorial Ependymoma

Symptoms & Phenotypes for Pediatric Infratentorial Ependymoma

UMLS symptoms related to Pediatric Infratentorial Ependymoma:


vomiting, headache, nausea

Drugs & Therapeutics for Pediatric Infratentorial Ependymoma

Drugs for Pediatric Infratentorial Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 3 58-05-9 143 6006
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
11
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Histamine Approved, Investigational Phase 3 51-45-6 774
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16 Folic Acid Antagonists Phase 3
17 Vitamin B9 Phase 3
18 Immunologic Factors Phase 3
19 Folate Phase 3
20 Nucleic Acid Synthesis Inhibitors Phase 3
21 Vitamin B Complex Phase 3
22 Immunosuppressive Agents Phase 3
23 Dermatologic Agents Phase 3
24 Antimetabolites, Antineoplastic Phase 3
25 Antimetabolites Phase 3
26 Antirheumatic Agents Phase 3
27 Antineoplastic Agents, Phytogenic Phase 3
28 Topoisomerase Inhibitors Phase 3
29 Etoposide phosphate Phase 3
30 Tubulin Modulators Phase 3
31 Alkylating Agents Phase 3
32 Antimitotic Agents Phase 3
33 Antineoplastic Agents, Alkylating Phase 3
34 Antiemetics Phase 3
35 Peripheral Nervous System Agents Phase 3
36 Autonomic Agents Phase 3
37 Emetics Phase 3
38 Gastrointestinal Agents Phase 3
39 Neurotransmitter Agents Phase 3
40 Anti-Allergic Agents Phase 3
41 Serotonin Antagonists Phase 3
42 Histamine H1 Antagonists Phase 3
43 Histamine Antagonists Phase 3
44 Serotonin Agents Phase 3
45
Histamine Phosphate Phase 3 51-74-1 65513
46 Antipruritics Phase 3
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Tamoxifen Approved Phase 2 10540-29-1 2733526
49
Sodium citrate Approved, Investigational Phase 2 68-04-2
50
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
5 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
6 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
7 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
8 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
9 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
10 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
11 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
12 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
13 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
14 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
15 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
16 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
17 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
18 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
19 Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
20 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
21 Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis Completed NCT00006246 Phase 1 busulfan
22 Phase I Study Of Cloretazine (VNP40101M) In Children With Recurrent, Progressive Or Refractory Primary Brain Tumors Completed NCT00098761 Phase 1 laromustine
23 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
24 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
25 Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms Completed NCT00003022 Phase 1
26 A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
27 Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
28 A Phase I Study of Valproic Acid in Children With Recurrent/Progressive Solid Tumors Including CNS Tumors Completed NCT00107458 Phase 1 valproic acid
29 A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
30 A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
31 A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
32 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
33 A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies Terminated NCT00572182 Phase 1 MK-0752
34 Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1 acetylcysteine;carboplatin;cyclophosphamide;etoposide phosphate;mannitol;sodium thiosulfate
35 A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children With Neoplastic Meningitis Terminated NCT00112619 Phase 1 topotecan hydrochloride
36 Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
37 A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias Withdrawn NCT00458744 Phase 1 talotrexin
38 Examination of the Multiple Genetic and Molecular Targets as Therapeutic Options for Patients With Ependymoma Treated by the Phase II Children's Oncology Group Study ACNS0121 Completed NCT01407744
39 Analyses of Mutations Associated With Secondary Leukemia or Non-Hodgkin's Lymphoma in Patients Treated for Hodgkin's Disease or Childhood Brain Tumors Completed NCT00006342
40 Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma Completed NCT00303810 carboplatin;cisplatin;cyclophosphamide;etoposide phosphate;high-dose chemotherapy;lomustine;methotrexate;thiotepa;vincristine sulfate
41 Barriers to Patient Enrollment Onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proportion of Enrollment Completed NCT00002485
42 Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas, Medulloblastoma/PNET and Gliomas of the Pediatric CNS Recruiting NCT00897286
43 CCLG Observational Study of the Outcome of Ependymoma in Infants Diagnosed Before Their Third Birthday Active, not recruiting NCT00683319 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
44 Immunologic Profile of Patients With Newly Diagnosed Medulloblastoma at Initial Diagnosis and During Standard Radiation and Chemotherapy Withdrawn NCT01233479 systemic chemotherapy
45 Evaluation of Cerebral Spinal Fluid (CSF) Proteome and Angiogenesis Proteins in Children With Newly Diagnosed Central Nervous System Tumors Withdrawn NCT00897858

Search NIH Clinical Center for Pediatric Infratentorial Ependymoma

Genetic Tests for Pediatric Infratentorial Ependymoma

Anatomical Context for Pediatric Infratentorial Ependymoma

MalaCards organs/tissues related to Pediatric Infratentorial Ependymoma:

41
Brain, Liver, Bone

Publications for Pediatric Infratentorial Ependymoma

Articles related to Pediatric Infratentorial Ependymoma:

# Title Authors PMID Year
1
Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. 38
27390862 2016
2
Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology. 38
21863401 2012
3
Evolution of neurological impairment in pediatric infratentorial ependymoma patients. 38
19330288 2009
4
Cervical subluxation after surgery and irradiation of childhood ependymoma. 38
12006754 2002
5
Isochromosome 1q as an early genetic event in a child with intracranial ependymoma characterized by molecular cytogenetics. 38
11672779 2001

Variations for Pediatric Infratentorial Ependymoma

Expression for Pediatric Infratentorial Ependymoma

Search GEO for disease gene expression data for Pediatric Infratentorial Ependymoma.

Pathways for Pediatric Infratentorial Ependymoma

Pathways related to Pediatric Infratentorial Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.51 MIR19A MIR17 MIR106B EZH2 EGFR
2
Show member pathways
11.5 MIR19A MIR17 MIR106B
3 11.18 MIR19A MIR17
4 10.91 LAMA2 EGFR

GO Terms for Pediatric Infratentorial Ependymoma

Biological processes related to Pediatric Infratentorial Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.61 MIR19A MIR17 MIR106B
2 cellular response to hypoxia GO:0071456 9.48 MIR17 MIR106B
3 response to estradiol GO:0032355 9.46 EZH2 EGFR
4 miRNA mediated inhibition of translation GO:0035278 9.4 MIR17 MIR106B
5 positive regulation of MAP kinase activity GO:0043406 9.37 EZH2 EGFR
6 positive regulation of fibroblast proliferation GO:0048146 9.32 MIR17 EGFR
7 liver regeneration GO:0097421 9.26 EZH2 EGFR
8 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.16 MIR19A MIR106B
9 negative regulation of sprouting angiogenesis GO:1903671 8.96 MIR19A MIR17
10 negative regulation of toll-like receptor signaling pathway GO:0034122 8.62 MIR19A MIR17

Molecular functions related to Pediatric Infratentorial Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.8 MIR19A MIR17 MIR106B

Sources for Pediatric Infratentorial Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....